Karyopharm Therapeutics is a biotechnology business based in the US. Karyopharm Therapeutics shares (KPTI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.85 – a decrease of 0.77% over the previous week. Karyopharm Therapeutics employs 325 staff and has a trailing 12-month revenue of around $145.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.85 |
|---|---|
| 52-week range | $0.62 - $1.95 |
| 50-day moving average | $0.79 |
| 200-day moving average | $1.02 |
| Wall St. target price | $4.36 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.14 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.8372 from 2024-10-15
| 1 week (2024-10-10) | -1.16% |
|---|---|
| 1 month (2024-09-17) | 11.58% |
| 3 months (2024-07-17) | -14.57% |
| 6 months (2024-04-17) | -39.33% |
| 1 year (2023-10-17) | -28.44% |
|---|---|
| 2 years (2022-10-17) | -83.05% |
| 3 years (2021-10-15) | 5.59 |
| 5 years (2019-10-17) | 10.86 |
| Revenue TTM | $145.7 million |
|---|---|
| Gross profit TTM | $151.9 million |
| Return on assets TTM | -31.98% |
| Return on equity TTM | -891.05% |
| Profit margin | -61.72% |
| Book value | $-1.06 |
| Market Capitalization | $104.4 million |
TTM: trailing 12 months
We're not expecting Karyopharm Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Karyopharm Therapeutics's shares have ranged in value from as little as $0.6174 up to $1.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Karyopharm Therapeutics's is 0.196. This would suggest that Karyopharm Therapeutics's shares are less volatile than average (for this exchange).
Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.